JACOBS-HOLDING-AG
17.4.2024 11:06:32 CEST | Business Wire | Press release
Jacobs Holding today announced that the board of directors has appointed Timothy Franks as Chief Executive Officer effective May 1, 2024.
With an impressive 25-year career at two prominent investment firms, Tim brings extensive experience and a proven track record in global private equity. His most recent role was as a Partner and Co-CEO of the democratized private equity business at KKR. He played a pivotal role in building KKR’s European franchise, leading the EMEA Core strategy, and overseeing the development of activities in the UK & Ireland, as well as the Consumer industry team in EMEA. Prior to that, Tim spent 17 years at Advent International, where he notably opened and led the New York office from 2010 to 2013. Throughout his tenure at both firms, he held various chair and board positions at portfolio companies.
Under his leadership, Jacobs Holding aims at further strengthening its investment activities, particularly in the services, healthcare and consumer industries. Tim’s strong investment focus on helping businesses with their sustainability and digitalization goals will be pivotal for Jacobs Holding in consolidating its investment approach, and investing in the growth potential of existing and future portfolio companies.
Nicolas and Philippe Jacobs, Co-Chairmen commented: “We are excited to have Tim join Jacobs Holding. Beyond being a highly accomplished private equity manager with an impressive track record, he has proven himself as a strong leader. Tim possesses all the qualities needed to get Jacobs Holding to the next level as a sustainable and entrepreneurial investor.”
Timothy Franks commented: “I look forward to working with the Jacobs team. It will be a real privilege to lead Jacobs Holding, given the strong purpose of the firm and its investment approach, which intersects three investment trends in alternative asset management: focusing on direct investments, pursuing a long-term investment horizon, and bringing sustainability and digitalization to the core of its activities.”
About Jacobs Holding AG
Jacobs Holding is a global professional investment firm founded by late entrepreneur Klaus J. Jacobs, in which he bundled his entrepreneurial activities in 1994. Jacobs Holding invests with a long-term horizon in companies active in non-cyclical businesses which already have or aim for a leading market position and have further growth and value creation potential. The current portfolio of Jacobs Holding consists of Cognita (www.cognita.com), Colosseum Dental Group (www.colosseumdental.com), North American Dental Group (www.nadentalgroup.com) as well as a large stake in the publicly traded company Barry Callebaut AG (www.barry-callebaut.com). The sole economic beneficiary of Jacobs Holding is the Jacobs Foundation, one of the world's leading charitable foundations for the promotion of development opportunities for children and young people. Since the foundation was established in 1989, around CHF 800 million has been paid out cumulatively.
Additional features:
File: JAG_CEO_English
File: Picture Timothy Franks
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417007318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom